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Abstract Tumors are characterized by their ability to avoid the 
host immune system. Ehrlich ascites tumor cells were used to 
investigate the early alterations of the host immune system after 
tumor inoculation. The results show that frequencies of splenic 
Th lymphocytes were drastically reduced during tumor growth, 
reaching a minimum only two days after tumor inoculation. The 
frequency of splenic CD4+ lymphocytes expressing IFN-y was 
significantly increased, although the total number was un-
changed, suggesting that there was no net induction of Thl-type 
response. Splenic macrophages were increased, in both frequency 
and cell number, after four days of tumor growth. The same 
pattern was observed when mice were inoculated with cell free 
ascitic fluid. TGF-|$ precursors were detected in tumor cells as 
well as in ascitic fluid. The data suggest that tumor actively 
interacts with host immune system by means of tumor cell 
secreted factors. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Host immune response to tumors is still not well under-
stood. A remarkable consequence of tumor growth is a de-
cline in the host immune function, partially explained by a 
diminished responsiveness of T lymphocytes and NK cells 
[1,2]. Other studies in mice inoculated with plasma cell and 
hepatoma tumors report that Th, but not cytotoxic lympho-
cytes are susceptible to tumor derived inhibitory factors, man-
ifested by a reduced proliferation of Th cells when they are 
stimulated with different mitogens [3,4]. Some mechanisms 
have been described that account for such immune suppres-
sion in tumor bearing hosts, including down-regulation of 
growth factors [5], production of immunosuppressive cyto-
kines [6,7], and the induction of suppressive macrophages 
[8-10,5] and T cells [11,2]. In addition, tumors are very 
poor in initiating effective immune responses; one reason 
for that is the lack of costimulation necessary to effectively 
activate T cells [12]. It has been proposed that the tumor 
induces a Th2-type response, which does not negatively affect 
the tumor, and depresses a Thl-type response which would 
promote tumor regression [13-15]. 
Mice bearing Ehrlich ascitic tumor, a rapidly growing ex-
perimental model, show several of the above indicated fea-
tures: reduced responsiveness of T cells to mitogens [16,17] 
and a progressive loss of splenic NK activity [9]. Macrophages 
are in part responsible for this suppressive effect [18,9]. In 
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other tumor models, macrophages have been shown to secrete 
a panel of immunosuppressive cytokines [7,19]; they also 
present low levels of MHC class II molecules [20] and induce 
oxidative stress that causes the disappearance of the CD3 t, 
chain of the T cell receptor complex [21]. 
Since host immune responses to tumor antigens are weak 
and not immediate [12], the early contacts between host and 
tumor are critical in determining the future directions of the 
immune response elicited by tumor secreted factors. Most 
tumor-host interaction studies are carried out when the tumor 
is well developed, actually reflecting the new steady state in-
duced by the tumor. The present model enables us to inves-
tigate, at earlier stages, the effects of the implantation of Ehr-
lich ascites tumor cells on the immune system of mice, as well 
as during the exponential tumor growth phase, revealing some 
alterations caused by tumor secreted products. Previous stud-
ies of our group have demonstrated that tumors induce early 
effects on host nitrogen metabolism [22,23]. 
2. Materials and methods 
2.1. Animals and tumor cells 
A hyperdiploid Lettre strain of Ehrlich ascites tumor cells was 
maintained in female albino Swiss CD1 mice (24-25 g), purchased 
from Criffa (Barcelona, Spain), as described elsewhere [24]. The life 
span of animals after inoculation with 5 X 106 tumor cells was 16 ± 1 
days. 
2.2. Antibodies 
Antibodies used were: Interferon-y (IFN-y) (rat IgGl, XMG 1.2) 
from Pharmingen (San Diego, California); Transforming growth fac-
tor^ (TGF-P) (polyclonal) from R&D Systems (Minnealopis, MN); 
CD4 (RM4-5) and CD18 (C71/16) from Sigma (St. Louis, MO). 
2.3. In vitro stimulation of spleen cells 
Mice were sacrificed by cervical dislocation. Spleens were homogen-
ated and cells incubated in RPMI medium containing 0.3 mg/ml glu-
tamine, 10% FCS (Whittaker), 100 units/ml Penicillin, 0.1 mg/ml 
Streptomycin and 1.25 units/ml Amphotericin B (Gibco BRL), in 
100 mm diameter petri dishes at 2X 106 cells/ml. Cells were stimulated 
for 5 h with 5 ng/ml PMA and 1 uM Ionomycin. Brefeldin A (Sigma) 
was added at 10 Jig/ml, using a stock of 1 mg/ml in ethanol, 2 h before 
the cells were harvested to prevent secretion of cytokines into the 
medium [25], Afterwards, the cells were washed and resuspended in 
PBS at 2X 106 cells/ml. Cells were fixed for 20 min at room temper-
ature by addition of 1 vol of 4% formaldehyde in PBS. Fixed cells 
were washed twice in PBS and resuspended in PBS containing 0.5% 
BSA and 0.02% NaN3 (buffer A) at 1-2 XlO
6 cells/ml. Cells were 
stored until processing at 4°C, in the dark. 
2.4. Cytokine stainings 
Spleen cells were analysed for production of IFN-y by intracellular 
staining as described by Assenmacher et al. [26]. Briefly, cells were 
incubated with the FITC-conjugated anti IFN-y antibody for 15 min 
at 1-2 X 106 cells/ml (room temperature) in buffer A containing 0.5% 
saponin, and washed once with the same buffer. For subsequent sur-
face staining, intracellularly stained cells were resuspended in buffer 
A. EAT cells were fixed and stained intracellularly with a pan-specific 
polyclonal antibody against TGF-p, detected with a biotinilated goat 
anti rabbit IgG and phycoerithrin conjugated streptavidin. Control 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00943-5 
2 J.A. Segura et al.lFEBS Letters 414 (1997) 1-6 
stainings were made using purified rabbit IgG from non immunized 
rabbits. 
All antibody incubations were supplemented with 10% normal 
mouse serum (Sigma) to prevent inspecific binding. Samples were 
analysed by flow cytometry in a FACSort apparatus with CellQuest 
software (Beckton Dickinson). 
2.5. Western blotting 
Ascitic fluid was analysed by analytical SDS-PAGE as described by 
Laemmli [27], using 5-15% gradient polyacrilamide gels. Samples were 
transferred to nitrocellulose membranes as described elsewhere [28] 
and protein stained with Ponceau red to control the plotting effi-
ciency. The membranes were then blocked for 2 h with a solution 
of 3% BSA in PBS containing 0.1% Tween-20 (TPBS). Incubations 
with the primary antibody at 1 iig/ml were performed overnight at 
4°C, followed by 3 washes with TPBS and incubated with the second 
antibody. Membranes were washed and the immune complexes were 
detected with a biotin-avidin peroxidase kit (Vectastain ABC kit; 
Vector Laboratories, Burlingame, CA) following the manufacturers 
directions. Finally the membranes were washed three times with 
PBS and color development was performed using 3-3' diaminobenzi-
dine tetrahydrochloride and 0.02% (v/v) H202 in 20 mM phosphate 
buffer pH 6. All antibodies were diluted with TPBS supplemented 
with 1% BSA. 
3. Results and discussion 
3.1. Tumor growth kinetics 
Ehrlich ascites tumor (EAT) cells were implanted in the 
peritoneal cavity of mice as described in Section 2. Exponen-
tial growth was observed until day 10 after inoculation, start-
ing a reduction in the number of cells at day 13 [29]. Mice 
were euthanized 10 days after tumor development. 
3.2. Effects of tumor growth on splenic Th and macrophage 
populations 
The aggressive behavior shown by the EAT cells causes 
dramatic changes in the energy and nitrogen metabolism of 
the host; our previous results have shown that as early as 24 h 
after tumor implantation, the plasma [24] and liver [23] con-
centrations of some amino acids change, and glutamine me-
tabolism is modified in order to satisfy the tumor needs [30]; 
questions arise whether or not the tumor also exerts early 
systemic effects on the host immune system. 
The designed experiment involved transplantation of mice 
with 5x 106 EAT cells at the exponential phase of growth, 7 
days after tumor inoculation. Mice were sacrificed after 1, 2, 4 
and 7 days of tumor growth and spleen cells were fixed in 
formaldehyde, stained and analysed by flow cytometry. Con-
trol mice were inoculated with the same volume of sterile 9 %o 
saline solution. The results shown in Fig. 1A demonstrated 
that the frequency of CD4+ lymphocytes rapidly diminished 
by 50% of controls in the spleen of mice after 2 days of tumor 
inoculation. Since changes in other splenic populations could 
alter the percentage of CD4+ cells, total splenic CD4+ lym-
phocytes were calculated. Total cell numbers in the spleen 
showed a progressive reduction until day 4 after tumor inoc-
ulation, but they were recovered at day 7 (results not shown). 
On the contrary, total CD4+ cells (Fig. IB) showed a more 
pronounced decrease and did not recover the original number, 
confirming the loss of CD4+ cells from the spleen. 
CD18+ macrophage frequencies remained unchanged at 
days 1 and 2 after tumor inoculation (Fig. 1), but later on, 
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Fig. 1. Frequencies and number of CD4+ and CD18+ cells in the spleen of tumor bearing mice. Mice were inoculated i.p. with 5X105 EAT 
cells (•); sterile saline were given to control mice (o). The spleen cells were fixed, stained with phycoerythrin-conjugated CD4 or CD18 anti-
bodies and analysed by flow cytometry. Data are represented as mean ± S.D. of at least 3 mice. Values significantly different from controls (us-
ing the U-Mann Whitney test) are marked with an asterisk * (p<0.01). 
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Fig. 2. Frequencies and number of splenic CD4+ IFN-y expressing and blast lymphocytes in the spleen of tumor bearing mice. Spleen cells 
were stimulated with PMA and lonomycin as described in Section 2. Tumor bearing mice are represented with full circles (•), and control 
mice with open circles (o). CD4+ blast frequencies were obtained by analysing forward and side scatter plots of CD4+ gated cells. Data are 
represented as mean±S.D. of at least 3 mice. Values significantly different from the controls (using the U-Mann Whitney test) are marked 
with * (p < 0.01) or ** (p < 0.05). 
at day 4, there was a dramatic increase in frequencies and 
total numbers in the spleens of tumor bearing mice. 
These results clearly show that the tumor induces early 
effects on the host immune system, reducing Th lymphocytes 
and increasing macrophage numbers and frequencies in the 
spleen of tumor bearing mice. Both affected cell populations, 
the Th lymphocytes and macrophages, are key targets in order 
to depress an effective immune response against the tumor 
invasion. In fact, a population of suppressive macrophages 
have been shown to be responsible for a diminished respon-
siveness of splenic lymphocytes to mitogens, and a suppres-
sion of the NK activity in mice inoculated with EAT cells 
[9,17] and other tumors [5,6,21]. Thus, Th cells seem to be a 
special target for the tumor signals. Ruzek et al. [3] observed a 
diminished proliferating response to mitogens of CD4+ lym-
phocytes, and not CD8+, in the spleen of mice bearing plasma 
cell tumors. Other authors have observed similar imbalances 
in lymphocytic and monocytic lineages. In the bone marrow 
of mice inoculated with EAT cells, lymphocytes of the null, 
Nkl . l and Thyl10 lineages are increased during the early 
growth of the tumor [31], in accordance with an enhanced 
hematopoietic activity [16]. In the spleen of mice implanted 
with mammary adenocarcinoma and Morris hepatoma there 
is an increased number of macrophages, exerting a suppressive 
activity [4,6], and in patients with gastric cancer, splenic NK 
and Th cells are present in lower frequencies compared to 
normal controls [2]. 
The reduced numbers of splenic Th lymphocytes in the 
tumor bearing mice is not explained by a reduction in the 
spleen size. In order to determine if those remaining lympho-
cytes had suppressed their capability for an effective cytokine-
mediated anti-tumor response, we evaluated, by intracellular 
staining, the frequency of IFN-y expressing Th lymphocytes in 
the spleen of tumor bearing mice after mitogenic stimulation. 
As can be seen in Fig. 2a, the frequency of IFN-y expressing 
Th lymphocytes slightly decayed at day 1 after tumor inocu-
lation, but it rapidly increased until day 7. This apparent 
activation was parallel to an increase in the frequency of 
CD4+ blast cells during tumor growth (Fig. 2b); and should 
reflect an activation process. Nevertheless, due to the progres-
sive loss of splenic CD4+ lymphocytes, the total number of 
IFN-y expressing CD4+ cells did not increase, but rather de-
creased until day 2 and did not reach the control numbers 
(Fig. 2c), indicating that there was not a net induction of 
IFN-y expression, but a selective loss of CD4+ cells not 
primed to express IFN-y in the spleen of tumor bearing 
mice. A similar pattern was shown by total CD4+ blast cells 
(Fig. 2d). If we interpret these results as a consequence of the 
immune response against the tumor, they would be in accord-
ance with the data suggesting that the tumor induces a Th 2-
like response while depressing or leaving the Th 1-like re-
sponse unaffected [3,13-15]. Moreover, the early effects of 
the tumor inoculation may suggest that a factor secreted by 
the tumor is giving rise to a loss of CD4+ cells in the spleen of 
tumor bearing mice. 
3.3. Effects of ascitic fluid inoculation on splenic Th and 
macrophage populations 
To test the possibility that the tumor secretes a humoral 
factor that may induce the observed effects on the host im-
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Fig. 3. Frequencies and number of splenic CD4+ and IFN-y expressing Th lymphocytes in the spleen of mice inoculated with ascitic fluid. 
5 mg of cell-free ascitic fluid of protein were daily inoculated to a panel of mice (•). Control mice were inoculated with sterile saline (o). 
Spleen cells from mice inoculated with ascitic protein were directly fixed for CD18 staining, or stimulated with PMA and lonomycin and fixed 
for IFN-y staining. Data are represented as mean ± S.D. of at least 3 mice. Values significantly different from the controls (using the U-Mann 
Whitney test) are marked with * (p<0.01) or ** (p<0.05). 
mime system, about 100 u.1 of cell free ascitic fluid (5 mg of 
total protein from 7-day tumor bearing mice) were daily in-
oculated to another group of healthy mice, and their spleens 
were obtained at days 1, 2 and 4 after beginning the experi-
ment. Healthy mice inoculated daily with equal volumes of 
sterile saline solution were used as controls. The results are 
shown in Fig. 3. Frequencies and total number of CD4+ lym-
phocytes were significantly decreased in animals inoculated 
with ascitic proteins (Fig. 3a and b), showing a similar pattern 
as that previously found in tumor bearing mice. Similarly, the 
frequencies of IFN-y expressing CD4+ lymphocytes were in-
creased in the spleen, although the number of cells reached 
control levels at day 4, after a pronounced reduction that was 
observed at day 1 (Fig. 3c and d). The frequency and number 
of CD18+ macrophages were also similar to those in tumor 
bearing mice (results not shown). 
The reduced number of CD4+ lymphocytes in the spleen 
together with the higher frequencies of IFN-y expressing 
CD4+ cells, suggest that previously activated lymphocytes 
would be selectively retained in the spleen of tumor bearing 
mice. It has been demonstrated that EAT cells produce a 
factor that inhibits lymphocyte migration [32]; in the same 
way, CD4+ T cells from patients with breast carcinoma in-
hibit T cell migration [33]. One possible explanation for a 
preferential retention of IFN-y expressing CD4+ cells in the 
spleen of tumor bearing mice, could be the inhibition of mi-
gration in preactivated lymphocytes. 
Suppressive macrophages are another source of inhibitory 
function; we have shown that both, the presence of the tumor 
and the cell-free ascitic fluid, induce an increase in both num-
ber and frequencies of splenic macrophages. In the EAT bear-
ing mice, macrophages actively inhibit T cell activation [9]; in 
the same way, a five fold increase in Mac-1+ splenic macro-
phages was described in mice with mammary adenocarcinoma 
[6]. 
The results shown suggest that some humoral factor(s) pro-
duced by the tumor may induce marked systemic effects on 
the host immune system. 
3.4. Presence of tumor secreted TGF-fi precursors in ascitic 
fluid of tumor bearing mice 
Ascitic fluid from mice bearing EAT cells has been previ-
ously shown to exert immunoregulatory activity, depressing 
splenic T cell polyclonal activation [32]. Many tumors pro-
duce soluble factors with pleiotropic activity that interact 
with the host immune system [33,34]. One of such a factor 
is the cytokine TGF-(3, that possesses angiogenic activity but 
it is also characterised for its ability to suppress immune re-
sponse [35]. Since EAT cells have been described to have TGF 
activity [36], we have made a first attempt to detect TGF-(3 in 
ascitic fluid of TBM as well as in EAT cells. Fig. 4 shows an 
immunoblotting of a gradient SDS gel containing ascitic fluid 
of 7 day TBM, revealed with a polyclonal pan-specific anti 
TGF-P antibody. Under non reducing conditions (Fig. 4a, 
lane 1), a single band of ca. 221 kDa can be observed, which 
agrees with the molecular weight of the latent high molecular 
weight complex of TGF-pi [37]. When reducing conditions 
were used (Fig. 4a, lane 2), a major band of ca. 72 kDa 
was detected, which corresponded with the molecular weight 
of the TGF-(3i precursor after reduction of all disulphide 
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Fig. 4. Detection of TGF-P in cell free ascitic fluid and Ehrlich cells, (a) Immunoblots analysis of ascitic fluid of 7 days TBM. Samples revealed 
with a polyclonal anti-TGF-P antibody. Lane 1, sample treated with 1 M P-mercaptoethanol (reducing conditions). Lane 2, sample with P-mer-
captoethanol omitted (non reducing conditions). Line 3: molecular weight markers: oc2-macroglobulin (193 kDa), P-galactosidase (112 kDa), 
fructose-6-phosphate kinase (70 kDa), fumarase (57 kDa), lactate dehydrogenase (39.5 kDa), triose-phosphate-isomerase (36 kDa). (b) Intracel-
lular stainings of EAT cells with anti TGF-P antibody (solid line). Control stainings were made using unrelated rabbit IgG as primary antibody 
(dotted line). 
bonds [37]. Furthermore, TGF-P was detected in EAT cells by 
intracellular staining (Fig. 4b) with the same antibody used 
for immunoblots. 
Active forms of TGF-Pi could not be detected in our assays 
in the ascitic fluid of TBM, which makes sense taking into 
account the potent anti-proliferative activity of TGF-(3. The 
activity of this cytokine is mainly regulated by its realising 
from the latent TGF-P complex and not by its secretion 
[38]. Physiologically, this is achieved by the presence of plas-
mine and urokinase; activated macrophages being one of the 
cell types that activates endogenous latent TGF-p [38]. In this 
way, tumor would ensure that TGF-P would exert its activity 
in the places where its needs are satisfied, i.e. in the host 
spleen. 
All the tumor effects on the host immune system are or-
chestrated to enhance its tumorigenicity. We have shown in 
mice with a highly malignant tumor (EAT cells), that early 
systemic effects could be induced by means of soluble factors 
secreted by the tumor. This rapid silencing of the host im-
mune response may be of critical importance in order to en-
sure tumor progression. It has been demonstrated that mice 
develop a strong and memory immune response against irra-
diated EAT cells [39,40], which reinforces the view that factors 
secreted by the tumor are crucial during the establishment of 
the tumor in the host. The characterization of such factors is 
important in order to prevent tumor growth and might allow 
an effective immune response against the tumor. 
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